Glox Therapeutics appoints Dr Michael Murray as Chair and Dr Nel Moore as SAB Member to support development of precision ...

Glox’s novel bacteriocin-based platform offers precision antibiotics that target resistant ... academia, and healthcare to ...

Antimicrobial packaging could help extend the shelf life of food, prevent illnesses, and reduce food waste. While there has been commercial interest in plastic food packaging containing ...

Collaborative Discovery Programme (CDP) funding introduced by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate. The funding of up to £500,000 is provided by LifeArc, a medical research ...

The tests aim to reduce the use of antibiotics and therefore antimicrobial resistance, which is rising globally. A pilot trial will begin later this year, applying the tests in rural settings with ...

leading to antimicrobial resistance (AMR). Glox Therapeutics’ proprietary protein bacteriocin engineering platform allows for the development of potent therapeutics that selectively eradicate ...

This typically requires antibiotic treatment; however, the bacteria may become resistant to antibiotics over time, leading to antimicrobial resistance (AMR). Glox Therapeutics’ proprietary protein ...

An explainable deep learning model enables the identification and virtual optimization of antimicrobial peptides (AMPs) from the oral microbiome, yielding novel AMPs with activity against ESKAPE ...